Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.

text 10 percentages discount 3d red white banner, letters and block, business concept — Truxima will launch at a 10% lower WAC than Rituxan • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. and Celltrion Inc. will launch Truxima (rituximab-abbs), the first biosimilar version of Roche's blockbuster lymphoma drug Rituxan (rituximab) in the US, on 11 November. It marks the first US biosimilar launch for Teva, a generic powerhouse that nonetheless fell behind rivals in the race to bring the first wave of biosimilars to market.

The wholesale acquisition cost (WAC) for Truxima will be 10% lower than branded Rituxan, Teva said in announcing the launch on 7 November. The WAC price for a 100mg vial will be $845.55 and $4,227.75 for a 500mg vial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.